Quantcast

Latest Vaccination Stories

2014-10-30 12:30:36

Coverage for Pneumococcal Vaccine Needed for Flu Season WASHINGTON, Oct. 30, 2014 /PRNewswire-USNewswire/ -- In August, the CDC's Advisory Committee on Immunization Practices (ACIP) made a decision to recommend a pneumococcal vaccine, PCV13, to seniors and other at-risk populations. ACIP's off-cycle meeting and prompt decision was to ensure that the updated recommendation was in place in time for this year's flu season. Following the decision, the recommendation was sent to the Centers for...

2014-10-29 16:30:07

MERIDEN, Conn., Oct. 29, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that the U.S. FDA has approved Flublok influenza vaccine for all adults aged 18 years and older, granting approval for use in people 50 and older under the accelerated approval of biological products regulations, 21 CFR 601.40-46. Flublok is the only licensed flu vaccine that is made using modern recombinant technology and the only flu vaccine that is 100% egg-free and highly purified. It also...

2014-10-29 16:30:03

ATLANTA, Oct. 29, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) announced today the approval of Pfizer's Trumenba, the first vaccine in the United States to prevent serogroup B meningococcal disease in individuals ages 10 to 25. Before today, vaccines licensed in the U.S. protected against four major strains of the disease: A, C, W and Y. They did not prevent serogroup B meningococcal disease, which accounts for one-third of U.S. cases. The National Meningitis...

2014-10-28 08:34:41

COSTA MESA, Calif., Oct. 28, 2014 /PRNewswire-iReach/ -- WCCT Global, a full Service Contract Research Organization headquartered in Southern California announced their involvement in a sentinel clinical trial designed to evaluate safety and immunogenicity signals from a novel oral vaccine for influenza, as opposed to injectable or intranasal vaccines. The study was first presented to the scientific community on October 14, 2014 at the World Vaccine Congress in Brussels, Belgium by...

2014-10-28 08:34:24

New report from Globe Life Sciences finds that combination therapy may be the key that finally allows cancer vaccines to fulfil their potential LONDON, October 28, 2014 /PRNewswire/ -- Globe Life Sciences, a leading provider of commercial analysis within healthcare-related sectors, conducted a detailed review of 17 late-stage cancer vaccines. The Globe Extraordinary report, entitled 'Future of Cancer Vaccines - An Analysis of Late-stage Products', concludes - after a history of...

2014-10-28 00:26:38

LONDON, Oct. 27, 2014 /PRNewswire/ -- This report analyzes the worldwide markets for Veterinary Vaccines in US$ Million by the following Product Segments: Companion Animal Vaccines (Canine Vaccines, & Feline Vaccines), and Livestock Vaccines (Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines, & Other Animal Vaccines). The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are...

2014-10-27 12:30:11

DUBLIN, Oct. 27, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global H1N1 Vaccines Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 H1N1 influenza (zoonotic) is an infectious disease in humans caused by a variant of the swine H1N1 virus, known as H1N1v virus. The H1N1v virus is a contagious virus which infects nose, throat, and lungs. H1N1 virus is an RNA virus belonging to the Orthomyxoviridae family. Influenza A...

2014-10-27 12:29:22

WORCESTER, Mass. and TORONTO, Oct. 27, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced two presentations demonstrating that the extent of the immunological response triggered by its novel proprietary cancer immunotherapeutic AE37 vaccine correlated with a reduction of relapse in breast cancer patients. The AE37 cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc....

2014-10-27 08:29:37

bioCSL to take on expanded role in global influenza vaccine industry MELBOURNE, Australia, Oct. 27, 2014 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL. Combining bioCSL's existing influenza vaccine operations with the Novartis business will create the number two global player in the US$4 billion global...

2014-10-23 08:36:59

WORCESTER, Mass. and TORONTO, Oct. 23, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be participating in the 2014 BIO-Europe(®) Annual International Partnering Conference being held November 3-5 in Frankfurt, Germany. BIO-Europe(®) is Europe's largest partnering conference serving the global biotechnology industry. The conference...


Latest Vaccination Reference Libraries

0_ac8af9115d7f37daaaa2af4dba273fb1
2011-01-11 14:17:29

The Cowpox virus causes a skin disease known as cowpox. It is related to the vaccinia virus and gained its name because it spread by dairymaids touching the udders of infected cows. It manifests as red blisters. It is similar to smallpox although much milder and was actually the basis of the first smallpox vaccine. A person who recovers from cowpox is immune to smallpox. In 1980 the World Health Organization announced that smallpox was the first disease to be eradicated world wide by a...

More Articles (1 articles) »
Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.